Agios Pharmaceuticals, Inc. (AGIO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
88 Sidney Street
Cambridge, MA 02139
United States of America (the)
Phone
617 649 8600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
540
First IPO Date
July 24, 2013
| Name | Title | Pay | Year Born |
| Brian Goff | Chief Executive Officer & Director | 1.45M | 1969 |
| Tak Wah Mak FRSC | Co-Founder | 50,000 | 1946 |
| Craig Thompson | Co-Founder | 50,000 | 1953 |
| Shin-San Su | Co-Founder | 50,000 | 1956 |
| Lewis Clayton Cantley | Co-Founder | 50,000 | 1949 |
| James William Burns | Chief Legal Officer | 780,510 | 1978 |
| Cecilia Jones | Chief Financial Officer | 791,835 | 1975 |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 887,232 | 1980 |
| Krishnan Viswanadhan | Chief Strategy & Operations Officer | 931,509 | 1979 |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer | 0 | 1982 |
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.